The veterinary medicinal product should be administered at a dose of 2.7 to 7 mg/kg bodyweight of afoxolaner in accordance with the following table The chewable tablets should not be divided. Monthly intervals throughout the flea and/or tick seasons In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 2 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. Can be used in pregnant and lactating dogs. Neurological disorders (convulsion, ataxia, muscle tremor)
afoxolaner 11.3 mg, chewable tablet for dogs 2-4 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
The veterinary medicinal product should be administered at a dose of 2.7 to 7 mg/kg bodyweight of afoxolaner in accordance with the following table The chewable tablets should not be divided. Monthly intervals throughout the flea and/or tick seasons In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 2 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. Can be used in pregnant and lactating dogs. Neurological disorders (convulsion, ataxia, muscle tremor)
afoxolaner 28.3 mg, chewable tablet for dogs >4-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
afoxolaner 68 mg, chewable tablet for dogs >10-25 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
a dose of 2.7 to 7 mg/kg bodyweight of afoxolaner use an appropriate combination of chewable tablets of different/same strengths Can be used in pregnant and lactating dogs.
afoxolaner 136 mg, chewable tablet for dogs >25-50 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
a dose of 2.7 to 7 mg/kg bodyweight of afoxolaner use an appropriate combination of chewable tablets of different/same strengths Can be used in pregnant and lactating dogs.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
Sources: VMD SPC · VMD
Warning(Dog)
In the absence of available data, treatment of puppies less than 8 weeks of age and dogs less than 1.35 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. The safety of NexGard has not been evaluated in dogs less than 8 weeks of age or less than 4 lbs body weight.
Sources: VMD SPC · VMD · FDA
Caution(Dog)
Afoxolaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Neurological signs (convulsion, ataxia and muscle tremor).
Sources: VMD SPC · VMD · FDA
Related products
Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.
Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.
For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.
Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.
The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.
